BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 19589279)

  • 1. Comparative analysis of protein expression in differentiated thyroid tumours: a multicentre study.
    Liang HS; Zhong YH; Luo ZJ; Huang Y; Lin HD; Luo M; ; Su HX; Zhou SB; Xie KQ
    J Int Med Res; 2009; 37(3):927-38. PubMed ID: 19589279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic value of 16 cellular tumor markers for metastatic thyroid cancer: an immunohistochemical study.
    Liang H; Zhong Y; Luo Z; Huang Y; Lin H; Zhan S; Xie K; Li QQ
    Anticancer Res; 2011 Oct; 31(10):3433-40. PubMed ID: 21965758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma.
    Liu YY; Morreau H; Kievit J; Romijn JA; Carrasco N; Smit JW
    Eur J Endocrinol; 2008 Mar; 158(3):375-84. PubMed ID: 18299472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CXC chemokine receptor 4 immunodetection in the follicular variant of papillary thyroid carcinoma: comparison to galectin-3 and hector battifora mesothelial cell-1.
    Torregrossa L; Faviana P; Filice ME; Materazzi G; Miccoli P; Vitti P; Fontanini G; Melillo RM; Santoro M; Basolo F
    Thyroid; 2010 May; 20(5):495-504. PubMed ID: 20450430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of malignancy markers in fine-needle aspiration cytology of thyroid nodules: comparison of Hector Battifora mesothelial antigen-1, thyroid peroxidase and dipeptidyl aminopeptidase IV.
    de Micco C; Savchenko V; Giorgi R; Sebag F; Henry JF
    Br J Cancer; 2008 Feb; 98(4):818-23. PubMed ID: 18212751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.
    Abd-El Raouf SM; Ibrahim TR
    Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced HBME-1 immunoreactivity of papillary thyroid carcinoma and papillary thyroid carcinoma-related neoplastic lesions with Hürthle cell and/or apocrine-like changes.
    Mai KT; Bokhary R; Yazdi HM; Thomas J; Commons AS
    Histopathology; 2002 Feb; 40(2):133-42. PubMed ID: 11952857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined immunohistochemistry for thyroid peroxidase, galectin-3, CK19 and HBME-1 in differential diagnosis of thyroid tumors.
    Paunovic I; Isic T; Havelka M; Tatic S; Cvejic D; Savin S
    APMIS; 2012 May; 120(5):368-79. PubMed ID: 22515291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of biomarkers for clinical diagnosis of papillary thyroid carcinoma with distant metastasis.
    Liang H; Zhong Y; Luo Z; Huang Y; Lin H; Luo M; Zhan S; Xie K; Ma Y; Li QQ
    Int J Biol Markers; 2010; 25(1):38-45. PubMed ID: 20306451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical Expression of HBME-1 and TROP-2 in Some Follicular-Derived Thyroid Lesions.
    Abu-Seadah SS; Attiah SM; Ali MY; Shams El-Din M; El-Kholy MA
    Asian Pac J Cancer Prev; 2023 Jul; 24(7):2305-2311. PubMed ID: 37505760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [HBME-1 immunostaining in thyroid pathology].
    Rigau V; Martel B; Evrard C; Rousselot P; Galateau-Salle F
    Ann Pathol; 2001 Feb; 21(1):15-20. PubMed ID: 11223556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma.
    Ito Y; Yoshida H; Tomoda C; Miya A; Kobayashi K; Matsuzuka F; Kakudo K; Kuma K; Miyauchi A
    Anticancer Res; 2005; 25(1A):179-82. PubMed ID: 15816536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions.
    Pavelić K; Dedivitis RA; Kapitanović S; Cacev T; Guirado CR; Danić D; Radosević S; Brkić K; Pegan B; Krizanac S; Kusić Z; Spaventi S; Bura M
    Mutat Res; 2006 Jul; 599(1-2):45-57. PubMed ID: 16698048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies.
    Buergy D; Weber T; Maurer GD; Mudduluru G; Medved F; Leupold JH; Brauckhoff M; Post S; Dralle H; Allgayer H
    Int J Cancer; 2009 Aug; 125(4):894-901. PubMed ID: 19480010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.
    McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoexpression of HBME-1, high molecular weight cytokeratin, cytokeratin 19, thyroid transcription factor-1, and E-cadherin in thyroid carcinomas.
    Choi YL; Kim MK; Suh JW; Han J; Kim JH; Yang JH; Nam SJ
    J Korean Med Sci; 2005 Oct; 20(5):853-9. PubMed ID: 16224162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of Immunocytochemistry on Cell Block Sections for the Investigation of Thyroid Lesions.
    Margari N; Giovannopoulos I; Pouliakis A; Mastorakis E; Gouloumi AR; Panayiotides IG; Karakitsos P
    Acta Cytol; 2018; 62(2):137-144. PubMed ID: 29339640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression of GADD153 in follicular tumors of thyroid and comparison with CK19, Galectin-3 and HBME-1].
    Tang QS; Teng XD; Ding W; Zhou J; Yao HT; Ying LX; Xu LM
    Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):745-8. PubMed ID: 22336157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of cytokeratin-19, galectin-3, and Hector Battifora mesothelial-1 in the diagnosis of benign and malignant thyroid nodules.
    Cui W; Sang W; Zheng S; Ma Y; Liu X; Zhang W
    Clin Lab; 2012; 58(7-8):673-80. PubMed ID: 22997967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Follicular variant of papillary carcinoma: reproducibility of histologic diagnosis and utility of HBME-1 immunohistochemistry and BRAF mutational analysis as diagnostic adjuncts.
    Wallander M; Layfield LJ; Jarboe E; Emerson L; Liu T; Thaker H; Holden J; Tripp S
    Appl Immunohistochem Mol Morphol; 2010 May; 18(3):231-5. PubMed ID: 20042852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.